BIIB021 (CNF2024) is a purine scaffold HSP90 inhibitor that binds to the ATP-binding pocket for HSP90 and blocks its chaperon function. HSP90 inhibition by BIIB021 leads to degradation of multiple oncogenic proteins and resulted in growth arrest and apoptosis.
BIIB021 is the first synthetic HSP90 inhibitor entered clinical trials and was evaluated in advanced solid tumor, gastrointestinal stromal tumors, B-cell chronic lymphocytic leukemia.
Technical information:
| Chemical Formula: | C14H15CIN6O | |
| CAS #: | 848695-25-0 | |
| Molecular Weight: | 318.76 | |
| Purity: | >98% | |
| Appearance: | White solid | |
| Chemical Name: | 6-chloro-9-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-9H-purin-2-amine | |
| Solubility: | Up to 50 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Lundgren K et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009;8:921-929. |
| 2. | Taldone T et al. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008;8(4): 370–374. |
Other Information:
Product Specification (pdf)
MSDS (pdf)
